ID   E2AK4_HUMAN             Reviewed;        1649 AA.
AC   Q9P2K8; C9JEC4; Q69YL7; Q6DC97; Q96GN6; Q9H5K1; Q9NSQ3; Q9NSZ5; Q9UJ56;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   12-OCT-2022, entry version 186.
DE   RecName: Full=eIF-2-alpha kinase GCN2 {ECO:0000250|UniProtKB:Q9QZ05};
DE            EC=2.7.11.1 {ECO:0000250|UniProtKB:Q9QZ05};
DE   AltName: Full=Eukaryotic translation initiation factor 2-alpha kinase 4 {ECO:0000312|HGNC:HGNC:19687};
DE   AltName: Full=GCN2-like protein;
GN   Name=EIF2AK4 {ECO:0000312|HGNC:HGNC:19687}; Synonyms=GCN2, KIAA1338;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 821-1649 (ISOFORM 1), AND VARIANT CYS-1306.
RC   TISSUE=Muscle, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 177-1649.
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI. The
RT   complete sequences of 150 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 196-1649, AND VARIANT LEU-441.
RC   TISSUE=Melanoma, and Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 831-1649.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1102-1649, AND TISSUE SPECIFICITY.
RX   PubMed=10504407; DOI=10.1046/j.1432-1327.1999.00780.x;
RA   Berlanga J.J., Santoyo J., de Haro C.;
RT   "Characterization of a mammalian homolog of the GCN2 eukaryotic initiation
RT   factor 2alpha kinase.";
RL   Eur. J. Biochem. 265:754-762(1999).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-667, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230 AND THR-667, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-667, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1259, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230 AND THR-667, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230; THR-667 AND THR-871, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   INVOLVEMENT IN PVOD2.
RX   PubMed=24135949; DOI=10.1378/chest.13-2366;
RA   Best D.H., Sumner K.L., Austin E.D., Chung W.K., Brown L.M., Borczuk A.C.,
RA   Rosenzweig E.B., Bayrak-Toydemir P., Mao R., Cahill B.C., Tazelaar H.D.,
RA   Leslie K.O., Hemnes A.R., Robbins I.M., Elliott C.G.;
RT   "EIF2AK4 mutations in pulmonary capillary hemangiomatosis.";
RL   Chest 145:231-236(2014).
RN   [17]
RP   TISSUE SPECIFICITY, AND VARIANTS PVOD2 GLN-585 AND ARG-643.
RX   PubMed=24292273; DOI=10.1038/ng.2844;
RA   Eyries M., Montani D., Girerd B., Perret C., Leroy A., Lonjou C.,
RA   Chelghoum N., Coulet F., Bonnet D., Dorfmueller P., Fadel E., Sitbon O.,
RA   Simonneau G., Tregouet D.A., Humbert M., Soubrier F.;
RT   "EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form
RT   of pulmonary hypertension.";
RL   Nat. Genet. 46:65-69(2014).
RN   [18]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=24310610; DOI=10.1126/science.1246829;
RA   Ravindran R., Khan N., Nakaya H.I., Li S., Loebbermann J., Maddur M.S.,
RA   Park Y., Jones D.P., Chappert P., Davoust J., Weiss D.S., Virgin H.W.,
RA   Ron D., Pulendran B.;
RT   "Vaccine activation of the nutrient sensor GCN2 in dendritic cells enhances
RT   antigen presentation.";
RL   Science 343:313-317(2014).
RN   [19]
RP   FUNCTION.
RX   PubMed=25329545; DOI=10.1042/bj20140852;
RA   Roobol A., Roobol J., Bastide A., Knight J.R., Willis A.E., Smales C.M.;
RT   "p58IPK is an inhibitor of the eIF2alpha kinase GCN2 and its localization
RT   and expression underpin protein synthesis and ER processing capacity.";
RL   Biochem. J. 465:213-225(2015).
RN   [20]
RP   FUNCTION.
RX   PubMed=26102367; DOI=10.1371/journal.pgen.1005212;
RA   Lehman S.L., Cerniglia G.J., Johannes G.J., Ye J., Ryeom S., Koumenis C.;
RT   "Translational Upregulation of an Individual p21Cip1 Transcript Variant by
RT   GCN2 Regulates Cell Proliferation and Survival under Nutrient Stress.";
RL   PLoS Genet. 11:E1005212-E1005212(2015).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-137; TRP-166; LEU-441; VAL-872;
RP   TYR-939; ARG-1060; CYS-1306; ARG-1336 AND HIS-1406.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Metabolic-stress sensing protein kinase that phosphorylates
CC       the alpha subunit of eukaryotic translation initiation factor 2
CC       (EIF2S1/eIF-2-alpha) in response to low amino acid availability
CC       (PubMed:25329545). Plays a role as an activator of the integrated
CC       stress response (ISR) required for adaptation to amino acid starvation
CC       (By similarity). EIF2S1/eIF-2-alpha phosphorylation in response to
CC       stress converts EIF2S1/eIF-2-alpha into a global protein synthesis
CC       inhibitor, leading to a global attenuation of cap-dependent
CC       translation, and thus to a reduced overall utilization of amino acids,
CC       while concomitantly initiating the preferential translation of ISR-
CC       specific mRNAs, such as the transcriptional activator ATF4, and hence
CC       allowing ATF4-mediated reprogramming of amino acid biosynthetic gene
CC       expression to alleviate nutrient depletion (By similarity). Binds
CC       uncharged tRNAs (By similarity). Required for the translational
CC       induction of protein kinase PRKCH following amino acid starvation (By
CC       similarity). Involved in cell cycle arrest by promoting cyclin D1 mRNA
CC       translation repression after the unfolded protein response pathway
CC       (UPR) activation or cell cycle inhibitor CDKN1A/p21 mRNA translation
CC       activation in response to amino acid deprivation (PubMed:26102367).
CC       Plays a role in the consolidation of synaptic plasticity, learning as
CC       well as formation of long-term memory (By similarity). Plays a role in
CC       neurite outgrowth inhibition (By similarity). Plays a proapoptotic role
CC       in response to glucose deprivation (By similarity). Promotes global
CC       cellular protein synthesis repression in response to UV irradiation
CC       independently of the stress-activated protein kinase/c-Jun N-terminal
CC       kinase (SAPK/JNK) and p38 MAPK signaling pathways (By similarity).
CC       Plays a role in the antiviral response against alphavirus infection;
CC       impairs early viral mRNA translation of the incoming genomic virus RNA,
CC       thus preventing alphavirus replication (By similarity).
CC       {ECO:0000250|UniProtKB:P15442, ECO:0000250|UniProtKB:Q9QZ05,
CC       ECO:0000269|PubMed:25329545, ECO:0000269|PubMed:26102367}.
CC   -!- FUNCTION: (Microbial infection) Plays a role in modulating the adaptive
CC       immune response to yellow fever virus infection; promotes dendritic
CC       cells to initiate autophagy and antigene presentation to both CD4(+)
CC       and CD8(+) T-cells under amino acid starvation (PubMed:24310610).
CC       {ECO:0000269|PubMed:24310610}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000250|UniProtKB:Q9QZ05};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000250|UniProtKB:Q9QZ05};
CC   -!- SUBUNIT: Homodimer; homodimerization is important for kinase activation
CC       by uncharged tRNAs. Interacts with GCN1; this interaction stimulates
CC       EIF2AK4/GCN2 kinase activity and is impaired by IMPACT upon a variety
CC       of stress conditions, such as amino acid depletion, UV-C irradiation,
CC       proteasome inhibitor treatment and glucose deprivation. Interacts with
CC       DNAJC3; this interaction inhibits EIF2AK4/GCN2 kinase activity during
CC       endoplasmic reticulum (ER), hypothermic and amino acid-starving stress
CC       conditions. {ECO:0000250|UniProtKB:P15442,
CC       ECO:0000250|UniProtKB:Q9QZ05}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9QZ05}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9P2K8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9P2K8-2; Sequence=VSP_013038;
CC       Name=3;
CC         IsoId=Q9P2K8-3; Sequence=VSP_039185, VSP_039186;
CC   -!- TISSUE SPECIFICITY: Widely expressed (PubMed:10504407). Expressed in
CC       lung, smooth muscle cells and macrophages (PubMed:24292273).
CC       {ECO:0000269|PubMed:10504407, ECO:0000269|PubMed:24292273}.
CC   -!- DOMAIN: The histidyl-tRNA synthetase-like region and protein kinase
CC       domains are necessary for eIF-2-alpha kinase activity and eIF-2-alpha-
CC       mediated translational control. The histidyl-tRNA synthetase-like
CC       domain is necessary for binding to uncharged tRNAs. Kinase domain 1 is
CC       a degenerate kinase domain. {ECO:0000250|UniProtKB:Q9QZ05}.
CC   -!- PTM: Autophosphorylated; autophosphorylation on Thr-899 is increased
CC       upon amino acid starvation and in UV irradiation cells and inhibited in
CC       presence of IMPACT. {ECO:0000250|UniProtKB:Q9QZ05}.
CC   -!- DISEASE: Pulmonary venoocclusive disease 2, autosomal recessive (PVOD2)
CC       [MIM:234810]: A disease characterized by widespread fibrous obstruction
CC       and intimal thickening of septal veins and preseptal venules, a low
CC       diffusing capacity for carbon monoxide, occult alveolar hemorrhage, and
CC       nodular ground-glass opacities, septal lines and lymph node enlargement
CC       showed by high-resolution computed tomography of the chest. It is
CC       frequently associated with pulmonary capillary dilatation and
CC       proliferation, and is a rare and devastating cause of pulmonary
CC       hypertension. {ECO:0000269|PubMed:24135949,
CC       ECO:0000269|PubMed:24292273}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA92576.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=BAB15625.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC012377; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC025168; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009350; AAH09350.2; -; mRNA.
DR   EMBL; BC078179; AAH78179.1; -; mRNA.
DR   EMBL; AB037759; BAA92576.1; ALT_SEQ; mRNA.
DR   EMBL; AL137627; CAB70849.1; -; mRNA.
DR   EMBL; AL157497; CAB75678.1; -; mRNA.
DR   EMBL; AL832907; CAH10626.1; -; mRNA.
DR   EMBL; AK027011; BAB15625.1; ALT_INIT; mRNA.
DR   EMBL; AJ243428; CAB58360.1; -; mRNA.
DR   CCDS; CCDS42016.1; -. [Q9P2K8-1]
DR   PIR; T46924; T46924.
DR   RefSeq; NP_001013725.2; NM_001013703.3. [Q9P2K8-1]
DR   PDB; 6N3L; X-ray; 2.61 A; A/B=577-657, A/B=782-1013.
DR   PDB; 6N3N; X-ray; 3.01 A; A=577-1013.
DR   PDB; 6N3O; X-ray; 2.40 A; A=577-1013.
DR   PDB; 7E2K; X-ray; 2.04 A; A=17-139.
DR   PDB; 7E2M; X-ray; 2.35 A; A/B/C/D/E/F=17-139.
DR   PDB; 7QQ6; X-ray; 2.80 A; A/B/C/D=577-1020.
DR   PDBsum; 6N3L; -.
DR   PDBsum; 6N3N; -.
DR   PDBsum; 6N3O; -.
DR   PDBsum; 7E2K; -.
DR   PDBsum; 7E2M; -.
DR   PDBsum; 7QQ6; -.
DR   AlphaFoldDB; Q9P2K8; -.
DR   SMR; Q9P2K8; -.
DR   BioGRID; 136426; 65.
DR   IntAct; Q9P2K8; 32.
DR   MINT; Q9P2K8; -.
DR   STRING; 9606.ENSP00000263791; -.
DR   BindingDB; Q9P2K8; -.
DR   ChEMBL; CHEMBL5358; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9P2K8; -.
DR   GuidetoPHARMACOLOGY; 2018; -.
DR   iPTMnet; Q9P2K8; -.
DR   PhosphoSitePlus; Q9P2K8; -.
DR   BioMuta; EIF2AK4; -.
DR   DMDM; 296439368; -.
DR   EPD; Q9P2K8; -.
DR   jPOST; Q9P2K8; -.
DR   MassIVE; Q9P2K8; -.
DR   MaxQB; Q9P2K8; -.
DR   PaxDb; Q9P2K8; -.
DR   PeptideAtlas; Q9P2K8; -.
DR   PRIDE; Q9P2K8; -.
DR   ProteomicsDB; 83838; -. [Q9P2K8-1]
DR   ProteomicsDB; 83839; -. [Q9P2K8-2]
DR   ProteomicsDB; 83840; -. [Q9P2K8-3]
DR   Antibodypedia; 22934; 429 antibodies from 36 providers.
DR   DNASU; 440275; -.
DR   Ensembl; ENST00000263791.10; ENSP00000263791.5; ENSG00000128829.12. [Q9P2K8-1]
DR   Ensembl; ENST00000559624.5; ENSP00000453148.1; ENSG00000128829.12. [Q9P2K8-3]
DR   GeneID; 440275; -.
DR   KEGG; hsa:440275; -.
DR   MANE-Select; ENST00000263791.10; ENSP00000263791.5; NM_001013703.4; NP_001013725.2.
DR   UCSC; uc001zkl.4; human. [Q9P2K8-1]
DR   CTD; 440275; -.
DR   DisGeNET; 440275; -.
DR   GeneCards; EIF2AK4; -.
DR   HGNC; HGNC:19687; EIF2AK4.
DR   HPA; ENSG00000128829; Low tissue specificity.
DR   MalaCards; EIF2AK4; -.
DR   MIM; 234810; phenotype.
DR   MIM; 609280; gene.
DR   neXtProt; NX_Q9P2K8; -.
DR   OpenTargets; ENSG00000128829; -.
DR   Orphanet; 275777; Heritable pulmonary arterial hypertension.
DR   Orphanet; 199241; Pulmonary capillary hemangiomatosis.
DR   Orphanet; 31837; Pulmonary venoocclusive disease.
DR   PharmGKB; PA134947616; -.
DR   VEuPathDB; HostDB:ENSG00000128829; -.
DR   eggNOG; KOG1035; Eukaryota.
DR   GeneTree; ENSGT00940000156798; -.
DR   HOGENOM; CLU_493107_0_0_1; -.
DR   InParanoid; Q9P2K8; -.
DR   OMA; GSEMIYE; -.
DR   OrthoDB; 64059at2759; -.
DR   PhylomeDB; Q9P2K8; -.
DR   TreeFam; TF101512; -.
DR   PathwayCommons; Q9P2K8; -.
DR   Reactome; R-HSA-9633012; Response of EIF2AK4 (GCN2) to amino acid deficiency.
DR   SignaLink; Q9P2K8; -.
DR   SIGNOR; Q9P2K8; -.
DR   BioGRID-ORCS; 440275; 64 hits in 1085 CRISPR screens.
DR   ChiTaRS; EIF2AK4; human.
DR   GeneWiki; EIF2AK4; -.
DR   GenomeRNAi; 440275; -.
DR   Pharos; Q9P2K8; Tchem.
DR   PRO; PR:Q9P2K8; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q9P2K8; protein.
DR   Bgee; ENSG00000128829; Expressed in adenohypophysis and 182 other tissues.
DR   ExpressionAtlas; Q9P2K8; baseline and differential.
DR   Genevisible; Q9P2K8; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0022626; C:cytosolic ribosome; ISS:UniProtKB.
DR   GO; GO:0005844; C:polysome; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004694; F:eukaryotic translation initiation factor 2alpha kinase activity; IMP:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0000049; F:tRNA binding; ISS:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IMP:UniProtKB.
DR   GO; GO:0070417; P:cellular response to cold; IMP:UniProtKB.
DR   GO; GO:1990253; P:cellular response to leucine starvation; ISS:UniProtKB.
DR   GO; GO:0034644; P:cellular response to UV; ISS:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0000077; P:DNA damage checkpoint signaling; IEA:InterPro.
DR   GO; GO:0036492; P:eiF2alpha phosphorylation in response to endoplasmic reticulum stress; IMP:UniProtKB.
DR   GO; GO:0140469; P:GCN2-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0007612; P:learning; ISS:UniProtKB.
DR   GO; GO:0007616; P:long-term memory; ISS:UniProtKB.
DR   GO; GO:0044828; P:negative regulation by host of viral genome replication; ISS:UniProtKB.
DR   GO; GO:0032792; P:negative regulation of CREB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0045947; P:negative regulation of translational initiation; ISS:UniProtKB.
DR   GO; GO:0032057; P:negative regulation of translational initiation in response to stress; ISS:UniProtKB.
DR   GO; GO:1990138; P:neuron projection extension; ISS:UniProtKB.
DR   GO; GO:0002821; P:positive regulation of adaptive immune response; ISS:UniProtKB.
DR   GO; GO:0002230; P:positive regulation of defense response to virus by host; ISS:UniProtKB.
DR   GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0071264; P:positive regulation of translational initiation in response to starvation; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0032268; P:regulation of cellular protein metabolic process; IEA:UniProt.
DR   GO; GO:0060259; P:regulation of feeding behavior; ISS:UniProtKB.
DR   GO; GO:0006446; P:regulation of translational initiation; ISS:UniProtKB.
DR   GO; GO:0010998; P:regulation of translational initiation by eIF2 alpha phosphorylation; IMP:UniProtKB.
DR   GO; GO:0002286; P:T cell activation involved in immune response; ISS:UniProtKB.
DR   GO; GO:0019081; P:viral translation; ISS:UniProtKB.
DR   Gene3D; 3.10.110.10; -; 1.
DR   Gene3D; 3.30.930.10; -; 1.
DR   Gene3D; 3.40.50.800; -; 1.
DR   InterPro; IPR045864; aa-tRNA-synth_II/BPL/LPL.
DR   InterPro; IPR036621; Anticodon-bd_dom_sf.
DR   InterPro; IPR016255; Gcn2.
DR   InterPro; IPR041715; HisRS-like_core.
DR   InterPro; IPR024435; HisRS-related_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR006575; RWD-domain.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR016135; UBQ-conjugating_enzyme/RWD.
DR   Pfam; PF12745; HGTP_anticodon2; 1.
DR   Pfam; PF00069; Pkinase; 3.
DR   Pfam; PF05773; RWD; 1.
DR   Pfam; PF13393; tRNA-synt_His; 1.
DR   PIRSF; PIRSF000660; Ser/Thr_PK_GCN2; 1.
DR   SMART; SM00591; RWD; 1.
DR   SMART; SM00220; S_TKc; 2.
DR   SUPFAM; SSF54495; SSF54495; 1.
DR   SUPFAM; SSF55681; SSF55681; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50908; RWD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activation of host autophagy by virus;
KW   Activator; Adaptive immunity; Alternative splicing; Antiviral defense;
KW   ATP-binding; Cell cycle; Coiled coil; Cytoplasm; Disease variant;
KW   Growth arrest; Host-virus interaction; Immunity; Kinase; Neurogenesis;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Repeat;
KW   RNA-binding; Serine/threonine-protein kinase; Stress response; Transferase;
KW   Translation regulation; tRNA-binding.
FT   CHAIN           1..1649
FT                   /note="eIF-2-alpha kinase GCN2"
FT                   /id="PRO_0000085947"
FT   DOMAIN          25..137
FT                   /note="RWD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00179"
FT   DOMAIN          296..539
FT                   /note="Protein kinase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          590..1001
FT                   /note="Protein kinase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..25
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          138..158
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          227..256
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          660..750
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          765..788
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1022..1493
FT                   /note="Histidyl-tRNA synthetase-like"
FT   COILED          146..205
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        140..158
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        706..720
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        765..783
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        848
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         596..604
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         619
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         230
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         667
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         871
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         899
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZ05"
FT   MOD_RES         904
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         1259
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   VAR_SEQ         608..616
FT                   /note="QNKLDGCCY -> WYRVIPSPL (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_039185"
FT   VAR_SEQ         617..1649
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_039186"
FT   VAR_SEQ         774..801
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_013038"
FT   VARIANT         137
FT                   /note="H -> R (in dbSNP:rs35509999)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040479"
FT   VARIANT         166
FT                   /note="R -> W (in dbSNP:rs34439704)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040480"
FT   VARIANT         441
FT                   /note="I -> L (in dbSNP:rs2291627)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:17974005"
FT                   /id="VAR_040481"
FT   VARIANT         585
FT                   /note="R -> Q (in PVOD2; dbSNP:rs587777106)"
FT                   /evidence="ECO:0000269|PubMed:24292273"
FT                   /id="VAR_070990"
FT   VARIANT         643
FT                   /note="L -> R (in PVOD2; dbSNP:rs757852728)"
FT                   /evidence="ECO:0000269|PubMed:24292273"
FT                   /id="VAR_070991"
FT   VARIANT         872
FT                   /note="D -> V (in dbSNP:rs34665481)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040482"
FT   VARIANT         939
FT                   /note="H -> Y (in a lung neuroendocrine carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040483"
FT   VARIANT         1060
FT                   /note="T -> R (in dbSNP:rs55781333)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040484"
FT   VARIANT         1306
FT                   /note="G -> C (in dbSNP:rs35602605)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040485"
FT   VARIANT         1336
FT                   /note="K -> R (in dbSNP:rs35480871)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040486"
FT   VARIANT         1406
FT                   /note="Q -> H (in dbSNP:rs55721315)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040487"
FT   CONFLICT        556
FT                   /note="E -> G (in Ref. 3; BAA92576 and 4; CAH10626)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        629
FT                   /note="Q -> K (in Ref. 4; CAH10626)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        858
FT                   /note="S -> F (in Ref. 5; BAB15625)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1133
FT                   /note="N -> I (in Ref. 6; CAB58360)"
FT                   /evidence="ECO:0000305"
FT   HELIX           19..34
FT                   /evidence="ECO:0007829|PDB:7E2K"
FT   HELIX           35..37
FT                   /evidence="ECO:0007829|PDB:7E2K"
FT   STRAND          38..40
FT                   /evidence="ECO:0007829|PDB:7E2K"
FT   STRAND          46..48
FT                   /evidence="ECO:0007829|PDB:7E2K"
FT   STRAND          54..59
FT                   /evidence="ECO:0007829|PDB:7E2K"
FT   STRAND          66..69
FT                   /evidence="ECO:0007829|PDB:7E2M"
FT   STRAND          70..78
FT                   /evidence="ECO:0007829|PDB:7E2K"
FT   TURN            81..84
FT                   /evidence="ECO:0007829|PDB:7E2K"
FT   STRAND          89..97
FT                   /evidence="ECO:0007829|PDB:7E2K"
FT   HELIX           100..116
FT                   /evidence="ECO:0007829|PDB:7E2K"
FT   TURN            117..119
FT                   /evidence="ECO:0007829|PDB:7E2K"
FT   HELIX           123..136
FT                   /evidence="ECO:0007829|PDB:7E2K"
FT   HELIX           585..589
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   STRAND          590..599
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   STRAND          602..609
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   TURN            610..612
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   STRAND          615..622
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   HELIX           628..640
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   STRAND          651..657
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   STRAND          797..803
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   HELIX           810..815
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   HELIX           818..820
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   HELIX           822..841
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   HELIX           851..853
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   STRAND          854..856
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   STRAND          862..864
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   STRAND          894..896
FT                   /evidence="ECO:0007829|PDB:7QQ6"
FT   HELIX           905..907
FT                   /evidence="ECO:0007829|PDB:6N3L"
FT   STRAND          912..915
FT                   /evidence="ECO:0007829|PDB:7QQ6"
FT   HELIX           924..937
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   HELIX           944..954
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   STRAND          957..959
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   TURN            964..966
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   STRAND          967..969
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   HELIX           972..981
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   HELIX           986..988
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   HELIX           992..997
FT                   /evidence="ECO:0007829|PDB:6N3O"
FT   STRAND          998..1000
FT                   /evidence="ECO:0007829|PDB:6N3N"
SQ   SEQUENCE   1649 AA;  186911 MW;  ECF3CFFA51AEE67C CRC64;
     MAGGRGAPGR GRDEPPESYP QRQDHELQAL EAIYGADFQD LRPDACGPVK EPPEINLVLY
     PQGLTGEEVY VKVDLRVKCP PTYPDVVPEI ELKNAKGLSN ESVNLLKSRL EELAKKHCGE
     VMIFELAYHV QSFLSEHNKP PPKSFHEEML ERRAQEEQQR LLEAKRKEEQ EQREILHEIQ
     RRKEEIKEEK KRKEMAKQER LEIASLSNQD HTSKKDPGGH RTAAILHGGS PDFVGNGKHR
     ANSSGRSRRE RQYSVCNSED SPGSCEILYF NMGSPDQLMV HKGKCIGSDE QLGKLVYNAL
     ETATGGFVLL YEWVLQWQKK MGPFLTSQEK EKIDKCKKQI QGTETEFNSL VKLSHPNVVR
     YLAMNLKEQD DSIVVDILVE HISGVSLAAH LSHSGPIPVH QLRRYTAQLL SGLDYLHSNS
     VVHKVLSASN VLVDAEGTVK ITDYSISKRL ADICKEDVFE QTRVRFSDNA LPYKTGKKGD
     VWRLGLLLLS LSQGQECGEY PVTIPSDLPA DFQDFLKKCV CLDDKERWSP QQLLKHSFIN
     PQPKMPLVEQ SPEDSEGQDY VETVIPSNRL PSAAFFSETQ RQFSRYFIEF EELQLLGKGA
     FGAVIKVQNK LDGCCYAVKR IPINPASRQF RRIKGEVTLL SRLHHENIVR YYNAWIERHE
     RPAGPGTPPP DSGPLAKDDR AARGQPASDT DGLDSVEAAA PPPILSSSVE WSTSGERSAS
     ARFPATGPGS SDDEDDDEDE HGGVFSQSFL PASDSESDII FDNEDENSKS QNQDEDCNEK
     NGCHESEPSV TTEAVHYLYI QMEYCEKSTL RDTIDQGLYR DTVRLWRLFR EILDGLAYIH
     EKGMIHRDLK PVNIFLDSDD HVKIGDFGLA TDHLAFSADS KQDDQTGDLI KSDPSGHLTG
     MVGTALYVSP EVQGSTKSAY NQKVDLFSLG IIFFEMSYHP MVTASERIFV LNQLRDPTSP
     KFPEDFDDGE HAKQKSVISW LLNHDPAKRP TATELLKSEL LPPPQMEESE LHEVLHHTLT
     NVDGKAYRTM MAQIFSQRIS PAIDYTYDSD ILKGNFSIRT AKMQQHVCET IIRIFKRHGA
     VQLCTPLLLP RNRQIYEHNE AALFMDHSGM LVMLPFDLRI PFARYVARNN ILNLKRYCIE
     RVFRPRKLDR FHPKELLECA FDIVTSTTNS FLPTAEIIYT IYEIIQEFPA LQERNYSIYL
     NHTMLLKAIL LHCGIPEDKL SQVYIILYDA VTEKLTRREV EAKFCNLSLS SNSLCRLYKF
     IEQKGDLQDL MPTINSLIKQ KTGIAQLVKY GLKDLEEVVG LLKKLGIKLQ VLINLGLVYK
     VQQHNGIIFQ FVAFIKRRQR AVPEILAAGG RYDLLIPQFR GPQALGPVPT AIGVSIAIDK
     ISAAVLNMEE SVTISSCDLL VVSVGQMSMS RAINLTQKLW TAGITAEIMY DWSQSQEELQ
     EYCRHHEITY VALVSDKEGS HVKVKSFEKE RQTEKRVLET ELVDHVLQKL RTKVTDERNG
     REASDNLAVQ NLKGSFSNAS GLFEIHGATV VPIVSVLAPE KLSASTRRRY ETQVQTRLQT
     SLANLHQKSS EIEILAVDLP KETILQFLSL EWDADEQAFN TTVKQLLSRL PKQRYLKLVC
     DEIYNIKVEK KVSVLFLYSY RDDYYRILF
//
